|
[1]
|
National Health Commission of the People’s Repbulic of China. The diagnosis and treatment protocol for COVID-19 patient (the 9th Edition, in Chinese). 2022. http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf. (In Chinese). [2022-4-17].http://www.nhc.gov.cn/yzygj/s7653p/202203/b74ade1ba4494583805a3d2e40093d88/files/ef09aa4070244620b010951b088b8a27.pdf |
|
[2]
|
Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection against the omicron variant from previous SARS-CoV-2 infection. N Engl J Med 2022;386(13):1288 − 90. http://dx.doi.org/10.1056/NEJMc2200133CrossRef
|
|
[3]
|
Suryawanshi RK, Chen IP, Ma TC, Syed AM, Brazer N, Saldhi P, et al. Limited cross-variant immunity after infection with the SARS-CoV-2 omicron variant without vaccination. medRxiv 2022. http://dx.doi.org/10.1101/2022.01.13.22269243CrossRef
|
|
[4]
|
Smith DJ, Hakim AJ, Leung GM, Xu WB, Schluter WW, Novak RT, et al. COVID-19 mortality and vaccine coverage - Hong Kong special administrative region, China, January 6, 2022-March 21, 2022. MMWR Morb Mortal Wkly Rep 2022;71(15):545 − 8. http://dx.doi.org/10.15585/mmwr.mm7115e1CrossRef
|
|
[5]
|
Magen O, Waxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of BNT162b2 mRNA COVID-19 vaccine in a nationwide setting. N Engl J Med 2022. http://dx.doi.org/10.1056/NEJMoa2201688CrossRef
|
|
[6]
|
European Centre for Disease Prevention and Control. SARS-CoV-2 variants of concern as of 7 April 2022. https://www.ecdc.europa.eu/en/COVID-19/variants-concern. [2022-4-17].https://www.ecdc.europa.eu/en/COVID-19/variants-concern |
|
[7]
|
Kawaoka Y, Uraki R, Kiso M, Iida S, Imai M, Takashita E, et al. Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2. Res Sq 2022. http://dx.doi.org/10.21203/rs.3.rs-1375091/v1.http://dx.doi.org/10.21203/rs.3.rs-1375091/v1 |
|
[8]
|
Plumb ID, Feldstein LR, Barkley E, Posner AB, Bregman HS, Hagen MB, et al. Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19-associated hospitalization among adults with previous SARS-CoV-2 Infection - United States, June 2021-February 2022. MMWR Morb Mortal Wkly Rep 2022;71(15):549 − 55. http://dx.doi.org/10.15585/mmwr.mm7115e2CrossRef
|
|
[9]
|
Temsah MH, Aljamaan F, Alenezi S, Alhasan K, Alrabiaah A, Assiri R, et al. SARS-CoV-2 omicron variant: exploring healthcare workers' awareness and perception of vaccine effectiveness: a national survey during the first week of WHO variant alert. Front Public Health 2022;10:878159. http://dx.doi.org/10.3389/fpubh.2022.878159CrossRef
|
|
[10]
|
Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, et al. SARS-CoV-2 BA variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. 1 Sci Transl Med 2022eabn8543. http://dx.doi.org/10.1126/scitranslmed.abn8543CrossRef
|
|
[11]
|
Rajpal VR, Sharma S, Kumar A, Chand S, Joshi L, Chandra A, et al. 'Is Omicron mild'? Testing this narrative with the mutational landscape of its three lineages and response to existing vaccines and therapeutic antibodies. J Med Virol 2022. http://dx.doi.org/10.1002/jmv.27749CrossRef
|
|
[12]
|
Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, et al. Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep 2022;71(13):495-502. http://dx.doi.org/10.15585/mmwr.mm7113e2.http://dx.doi.org/10.15585/mmwr.mm7113e2 |
|
[13]
|
Glatman-Freedman A, Bromberg M, Hershkovitz Y, Sefty H, Kaufman Z, Dichtiar R, et al. Effectiveness of BNT162b2 vaccine booster against SARS-CoV-2 infection and breakthrough complications, israel. Emerg Infect Dis 2022;28(5):948 − 56. http://dx.doi.org/10.3201/eid2805.220141CrossRef
|